Amalgamated Bank’s Standard BioTools LAB Stock Holding History

Amalgamated Bank’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,404	Closed	-$12K	–	2262
2025 Q4	$12K	Sell	9,404 -1,034	-10%	-$1.39K	﹤0.01%	2342
2025 Q3	$14K	Hold	10,438	–	–	﹤0.01%	2305
2025 Q2	$13K	Hold	10,438	–	–	﹤0.01%	2316
2025 Q1	$11K	Hold	10,438	–	–	﹤0.01%	2323
2024 Q4	$18K	Hold	10,438	–	–	﹤0.01%	2155
2024 Q3	$20K	Hold	10,438	–	–	﹤0.01%	2136
2024 Q2	$18K	Buy	+10,438	New	+$25.5K	﹤0.01%	2167
2022 Q2	–	Sell	-9,549	Closed	-$34K	–	3128
2022 Q1	$34K	Sell	9,549 -700	-7%	-$2.42K	﹤0.01%	2632
2021 Q4	$40K	Sell	10,249 -311	-3%	-$1.46K	﹤0.01%	2116
2021 Q3	$70K	Sell	10,560 -315	-3%	-$2.07K	﹤0.01%	2110
2021 Q2	$67K	Buy	+10,875	New	+$58.1K	﹤0.01%	2148
2020 Q2	–	Sell	-12,377	Closed	-$31K	–	1568
2020 Q1	$31K	Buy	12,377 +53	+0.4%	+$174	﹤0.01%	1598
2019 Q4	$43K	Hold	12,324	–	–	﹤0.01%	1798
2019 Q3	$57K	Sell	12,324 -140	-1%	-$1.1K	﹤0.01%	1698
2019 Q2	$154K	Buy	+12,464	New	+$159K	﹤0.01%	1635

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Amalgamated Bank's LAB Position: Q1 2026 in Review

Amalgamated Bank sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 9,404 shares — an estimated $12K sold.

Amalgamated Bank first reported a position in LAB in Q2 2019 and held it in 15 quarters. The position peaked at $154K in Q2 2019. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Amalgamated Bank reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 9,404 Standard BioTools shares in Q1 2026, an estimated $12K.
Amalgamated Bank first reported a position in Standard BioTools in Q2 2019 and held it in 15 quarters.
Amalgamated Bank's Standard BioTools position peaked at $154K in Q2 2019.
156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.